--- a
+++ b/clusters/3009knumclusters/clust_250.txt
@@ -0,0 +1,533 @@
+Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by multi-gated acquisition (MUGA)
+Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower, as determined by echocardiogram or multi-gated acquisition (MUGA) scan within 4 weeks of randomization
+Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 30 days of day 1 of study
+Cardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= institutional lower limit of normal by multi gated acquisition scan (MUGA)/radionuclide ventriculogram (RVG) or echocardiogram (ECHO)
+Shortening fraction of >= 27% by echocardiogram, or
+Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional [D] echocardiogram is preferred; however, multi gated acquisition [MUGA] scan may be substituted based on institutional preferences;) the LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal
+Patients must have a left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) within 28 days prior to registration
+Patient must have a normal cardiac ejection fraction by pretreatment multigated acquisition scan (MUGA) or echocardiogram within 4 weeks prior to registration (resting ejection fraction >= 40% or >= 5% increase with exercise), shortening fraction by echocardiogram >= 24%, or to within the normal range of values for the institution
+Patients must have an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 42 days prior to registration with a cardiac ejection fraction >= 45%
+Patients must have an echocardiogram (ECHO) or a nuclear study (multi-gated acquisition scan [MUGA] or first pass) within 4 weeks (28 days) prior to registration to treatment and must not have a left ventricular ejection fraction (LVEF) < institutional lower limit of normal (LLN); if the LLN is not defined at a site, the LVEF must be > 50% for the patient to be eligible
+Shortening fraction of >= 27% by echocardiogram, or
+New York Heart Association class I or less; ordinary physical activity does not cause undue fatigue, palpitations, dyspnea, or angina pain; patients 60 years or older must have a left ventricular ejection fraction (LVEF) at rest >= 40% measured by echocardiogram or multi-gated acquisition (MUGA)
+Shortening fraction of >= 27% by echocardiogram, or
+Shortening fraction of >= 27% by echocardiogram
+Left ventricular ejection fraction (LVEF) > lower limit of normal (LLN) based on cardiac echocardiography (ECHO) or multi-gated acquisition (MUGA)
+Left ventricular ejection fraction > 50% as measured by echocardiogram or multi gated acquisition (MUGA) scan
+Left ventricular ejection fraction >= 50%, as determined by multigated acquisition (MUGA) or echocardiogram within 30 days prior to protocol registration
+Cardiac ejection fraction >= 50% (for HER2+ patients) as assessed by echocardiogram, multi gated acquisition scan (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO); ECHO scans must be used throughout the study when indicated
+Left ventricular ejection fraction >= 50% by transthoracic echocardiography or multi-gated acquisition scan (MUGA) within 28 days prior to the first dose of the study drug
+Patients must not have a cardiac ejection fraction < 45% or the presence of New York Heart Association stage III or IV heart failure within 14 days prior to registration; either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) may be used to determine ejection fraction
+Patients must have left ventricular ejection fraction (LVEF) >= 50 as measured by echocardiogram or multigated acquisition scan (MUGA)
+Patients with an ejection fraction < 50% assessed by multigated acquisition scan (MUGA) or echocardiogram (ECHO) scan within 7 days of day 1
+Cardiopulmonary dysfunction, including inadequate left ventricular ejection function at baseline, less than 50% by either echocardiogram or multiple-gated acquisition scan
+Left ventricular ejection fraction (LVEF) determined by echocardiogram or multi-gated acquisition scan ? 50%
+Patients with a cardiac ejection fraction (as measured by either Multi Gated Acquisition [MUGA] or echocardiogram [EKG]) < 40%
+Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram or multigated acquisition scan (MUGA) documented within 28 days prior to first dose of study drug
+Participants with a history of chronic heart failure or significant cardiovascular disease must have an echocardiogram or multigated acquisition scan indicating left ventricular ejection fraction greater than or equal to 45% within 28 days prior to the first dose of study drug.
+Left ventricular ejection fraction (LVEF) >= 50% by 2-dimensional (2D) echocardiogram (ECHO) or multigated acquisition (MUGA) scan; timeline: within 4 weeks prior to enrollment
+Prior or current cardiomyopathy including but not limited to the following: known hypertrophic cardiomyopathy, known arrhythmogenic right ventricular cardiomyopathy, previous moderate or severe impairment of left ventricular systolic function (left ventricular ejection fraction [LVEF] < 45% on echocardiography or equivalent on multigated acquisition scan [MuGA]) even if full recovery has occurred
+Cardiac function: Left ventricular ejection fraction (LVEF) > 40%; or LV shortening fraction > 26% by cardiac echocardiogram or by Multi Gated Acquisition Scan (MUGA).
+Baseline ejection fraction ? 50% as assessed by echocardiogram or multi-gated acquisition (MUGA) scan.
+Left ventricular ejection fraction (LVEF) within 5 absolute percentage points of institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 28 days prior to study registration (i.e., if the institutional normal is 50%, subject’s LVEF may be as low as 45% to be eligible for the study)
+Left ventricular ejection fraction (LVEF) greater than 50% on echocardiography or multiple gated acquisition (MUGA) scan
+Left ventricular ejection fraction of > 50% on baseline echocardiography or multi-gated acquisition (MUGA) scan
+Left ventricular ejection fraction; LVEF >= 40% (by echocardiogram or multigated acquisition scan [MUGA] testing)
+For Part F (LY2835219 + trastuzumab):The participant must have received at least 1 chemotherapy regimen for metastatic disease and may be receiving ongoing therapy with trastuzumab. The participant must have an estimated left ventricular ejection fraction within the normal range by either echocardiogram or multigated acquisition (MUGA) scan
+Normal left ventricular ejection fraction of >= 50% estimated by multi gated acquisition (MUGA) scan or echocardiogram
+Left ventricular ejection fraction >= 50% on echocardiogram or multi gated acquisition scan (MUGA) scan
+Patients with symptomatic left ventricular dysfunction or baseline left ventricular ejection fraction (LVEF) my multigated acquisition scan (MUGA) or echocardiogram (ECHO) of =< 50% are not eligible
+Left ventricular ejection fraction (LVEF) >= 50% (determined by echocardiogram or multigated acquisition scan) within 42 days of treatment
+Ejection fraction of < 45% by either multi gated acquisition scan (MUGA) or echocardiogram (ECHO)
+Left ventricular ejection fraction (LVEF) of 50% or greater, as measured by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan, within 28 days before the first dose of TAK-580
+Participants must have adequate cardiac function, e.g. left ventricular ejection fraction (LVEF) of > 50% as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); corrected QT interval (QTc) < 470ms
+Left ventricular ejection fraction (LVEF) ? 50% by echocardiogram (echo) or multigated acquisition (MUGA) scan within 28 days before day 1 of study
+Have a left ventricular ejection fraction (LVEF) >45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
+Left ventricular ejection fraction (LVEF) < 45% as determined by multi-gated acquisition scan (MUGA) or echocardiogram (ECHO).
+On echocardiogram, documented left ventricular ejection fraction > 45%; patients may instead have a multigated acquisition (MUGA) scan instead of transthoracic echocardiogram (TTE).
+Participant has a left ventricular ejection fraction (LVEF) <50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO);
+Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>=) 53 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans
+ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram or multigated acquisition scan (MUGA)
+EXPANDED ACCESS COHORT: Participants must have adequate cardiac function, defined as:\r\n* Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram (ECHO) or MUGA\r\n* QTcF =< 480 msec on screening electrocardiogram (ECG)
+Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality, including any of the following:\r\n* History of angina pectoris, symptomatic pericarditis, coronary artery bypass graft (CABG) or myocardial infarction within 6 months prior to study entry\r\n* Documented cardiomyopathy\r\n* Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening
+Left ventricular cardiac ejection fraction of ?45% by echocardiogram or multigated acquisition (MUGA) scan
+Patients must have normal left ventricular systolic function, as demonstrated by a transthoracic echocardiogram or multi-gated acquisition scan (MUGA) scan showing a normal left ventricular ejection fraction
+Cardiac: Left ventricular ejection fraction (LVEF) at rest ? 40%. For patients aged < 13 years, shortening fraction (SF) ? 26% by echocardiogram or Multi Gated Acquisition Scan (MUGA) may be substituted for LVEF.
+Left ventricular ejection fraction >= 45% by multigated acquisition scan (MUGA) or echocardiogram
+Patients must not have presence of class III or IV heart failure, according to New York Heart Association classifications, or a known left ventricular ejection fraction of less than 50%; Note: left ventricular ejection fraction (LVEF) evaluation by echocardiogram or multi-gated acquisition scan (MUGA) is not required prior to registration
+Left ventricular ejection fraction >= 40% by 2 dimensional (D) echocardiogram (ECHO) or multigated acquisition (MUGA) scan, or left ventricular shortening fraction >= 20% by ECHO for patients receiving MAC, RIC or RIC-MMF, or LVEF > 30%; if the patient has radiologic evidence of aortic, renal, or coronary artery vasculitis, LVEF >= 30% for patients receiving IOC
+Normal ejection fraction (echocardiogram [ECHO]) >= 53% (if a range is given then the upper value of the range will be used) or cardiac MRI
+Normal cardiac function, as determined by left ventricular ejection fraction (LVEF) >= institutional lower limit of normal on echocardiogram or multi-gated acquisition scan (MUGA) within 1 month of registration
+Ejection fraction < 40% obtained by either multi gated acquisition scan (MUGA) or echocardiogram
+Left ventricular ejection fraction (LVEF) > 50% as assessed by echocardiogram or MUGA (multi gated acquisition scan)
+Shortening fraction > 28% by echocardiogram or Ejection Fraction of > 50 % by multigated acquisition (MUGA)
+Screening calculated LVEF of ?50% by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan
+Normal cardiac ejection fraction (> 50%) by multi gated acquisition scan (MUGA) or echocardiogram
+Adequate cardiac function defined as an ejection fraction of >= 50% by multi gated acquisition scan (MUGA) scan or echocardiogram and a corrected QT (QTc) interval of =< 450 ms for men and =< 460 ms for women
+Baseline multi-gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%.
+Patients with a cardiac ejection fraction (as measured by either multi-gated acquisition [MUGA] or echocardiogram) < 40%
+Left ventricular ejection fraction (LVEF) must be equal to or greater than 50%, as measured by multigated acquisition (MUGA) scan or echocardiogram
+Ejection fraction measured by echocardiogram or multigated acquisition (MUGA) >= 50%
+Baseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) done only in subjects with prior doxorubicin exposure. The test must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
+A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of >= 50% established by multi-gated acquisition scan (MUGA) or echocardiogram
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) as assessed by either multigated acquisition (MUGA) scan or echocardiogram (ECHO)
+Have current or a history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (left ventricular ejection fraction [LVEF] < 40%, as measured by multigated acquisition [MUGA] scan or echocardiogram)
+Ejection fraction < 50% on screening echocardiography (ECHO) or multigated acquisition scan (MUGA).
+Cardiac ejection fraction within institutional normal limits by either multigated acquisition scan (MUGA) or echocardiogram (ECHO) at baseline
+Left ventricular ejection fraction (LVEF) above institutional lower limit of normal (by echocardiogram or multi-gated acquisition [MUGA] scan within 90 days of registration)
+If the participant is to be enrolled in the doxorubicin combination arm, a left ventricular dysfunction (LVEF < 50%) or shortening fraction of <27% by echocardiogram (either multigated acquisition [MUGA] or echocardiogram [ECHO] are required, not both).
+Must be hemodynamically stable at the time of ET190L1-ARTEMIS T cell administration and have left ventricular ejection fraction (LVEF) ? 45% confirmed by echocardiogram or multigated acquisition scan (MUGA) scan
+Left ventricular ejection fraction determined by echocardiogram or multiple-gated acquisition scan (MUGA) (cardiac scan) must be 50% or higher
+Shortening fraction >= 28% by echocardiogram OR ejection fraction of >= 50 % by multigated acquisition (MUGA)
+Shortening fraction of >= 27% by echocardiogram, OR
+Ejection fraction of >= 50% by gated radionuclide study/echocardiogram
+Left ventricular ejection fraction (LVEF as determined by cardiac echo or MUGA scan) below the normal limits of the institutions specific testing range. This assessment may be repeated once at the discretion of the Investigator with the approval of the Sponsor.
+Within 4 weeks before enrollment: Left ventricular ejection fraction (LVEF) > 45% by multigated acquisition (MUGA) or rest echocardiogram (ECHO)
+Left ventricular ejection fraction (LVEF) > 40% or LV shortening fraction > 26% by cardiac echocardiogram or by multi-gated acquisition (MUGA) scan
+Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) of >= 50% as assessed by echocardiogram or multigated acquisition (MUGA) scan, or LVEF of 45-49% and clearance by a cardiologist
+Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) of ? 50% as assessed by echocardiogram or MUGA scan, or LVEF of 45-49% and clearance by a cardiologist; if subject receives cardiotoxic chemotherapy after enrollment, repeat echocardiogram or MUGA is required to reestablish eligible LVEF
+Left ventricular ejection fraction (LVEF) ? 55% at rest (multigated acquisition [MUGA] scan or echocardiogram [Echo])
+Left ventricular ejection fraction greater than (>) 50% as measured by ECHO or MUGA scan within 4 weeks before receiving the first dose of study drug.
+Has left ventricular ejection fraction (LVEF) < 45% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan.
+Shortening fraction >= 28% by echocardiogram or ejection fraction of >= 50 % by multigated acquisition (MUGA)
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiography (ECHO) or multigated acquisition (MUGA)
+Cardiac echocardiogram, stress test, or multigated acquisition (MUGA) within past 6 months with demonstrated left ventricular ejection fraction (LVEF) > 50%
+Patients with New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 40% by echocardiogram or multi-gated acquisition (MUGA) scan
+Shortening fraction of >= 27% by echocardiogram OR
+Left ventricular ejection fraction >= 50% measured by multigated acquisition (MUGA) scan or echocardiogram
+If a patient has received anthracycline chemotherapy after prior enrollment on PLAT-02, they must have an echocardiogram to demonstrate shortening fraction > 28% or multigated acquisition scan (MUGA) to demonstrate ejection fraction of > 50%; the echocardiogram or MUGA can be done at any time following the anthracycline (does NOT need to be within 48 hours of the T cell infusion)
+Shortening fraction > 28% by echocardiogram or ejection fraction of > 50 % by MUGA
+Ejection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)\r\n> 50%.
+Left ventricular ejection fraction of 50% or more at baseline (by echocardiography or multiple-gated acquisition scanning)
+(For cohort B): Baseline multigated acquisition (MUGA) or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% within 6 weeks prior to initiation of NACT
+Left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA) scan performed within 1 month before starting lymphodepleting chemotherapy
+Left ventricular ejection fraction (LVEF) assessment by 2-dimensional (D) echocardiogram or multi-gated acquisition (MUGA) scan performed within 90 days prior to registration must be >= 50%
+Left ventricular ejection fraction (LVEF) >= 50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
+Symptomatic congestive heart failure (New York Heart Association III-IV) or documented cardiomyopathy with left ventricular ejection fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening. MUGA/ ECHO to be performed within 28 days prior to registration.
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
+Impaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
+Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi-gated acquisition (MUGA)
+Left ventricular ejection fraction (LVEF) >= 40% by echocardiography or multi-gated acquisition scan (MUGA) or cardiac magnetic resonance imaging (MRI), no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
+Impaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by echocardiography (ECHO) or radionuclide ventriculogram (MUGA) scan
+Left ventricular ejection fraction (LVEF as determined by cardiac echo or MUGA scan) below the normal limits of the institutions specific testing range. This assessment may be repeated once at the discretion of the Investigator with the approval of the Sponsor.
+Cardiac ejection fraction >= 50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO) or multiple-gated acquisition (MUGA), and no clinically significant electrocardiography (ECG) findings
+Left ventricular ejection fraction (LVEF) >= 40% by echocardiography or multi-gated acquisition scan (MUGA), no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
+Left ventricular ejection fraction (LVEF) >/= 50 percent (%) on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
+Adequate cardiac function defined as an ejection fraction on echocardiogram (ECHO) or multi-gated acquisition (MUGA) that is at or above the institutional normal limits
+Left ventricular ejection fraction (LVEF) within 5 absolute percentage points of institutional standard of normal (50-70%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration (ie, if the institutional normal is 50%, subject’s LVEF may be as low as 45% to be eligible for the study)
+CELL PROCUREMENT: Subjects must not have left ventricular ejection fraction of < 40% (shortening fraction < 27% for pediatric subjects) as measured by echocardiogram or multi-gated acquisition (MUGA)
+Left ventricular ejection fraction (LVEF) >= 45%, assessed within 3 months prior to registration, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality
+Ejection fraction of >= 50% by echocardiogram or multi-gated acquisition (MUGA) scan
+Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 40%; for children that are not able to cooperate with multi-gated acquisition (MUGA) and echocardiography, such should be clearly stated in the physician’s note
+Patient has no significant ischemic heart disease or myocardial infarction (MI) within 6 months before the first dose of TVB 2640 and currently has adequate cardiac function, as evidenced by a left ventricular ejection fraction (LVEF) of >= 50% as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); and corrected QT interval (QTc) < 470 msec on screening electrocardiogram (EKG)
+Left ventricular ejection fraction (LVEF) assessment (i.e., 2 dimensional [2-D] echocardiogram or multi-gated acquisition [MUGA] scan) performed within 12 weeks prior to study registration indicates an LVEF >= 50% regardless of the cardiac imaging facility’s lower limit of normal
+Patients must have a shortening fraction >= 27% or left ventricular ejection fraction >= 50% measured by echocardiogram (ECHO) or measured by multiple-gated acquisition scans (MUGA)
+Left ventricular ejection fraction (LVEF) of lesser than [<] 50 percent (%) as determined by multiple uptake gated acquisition (MUGA) or echocardiography during screening
+A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of 50% established by multi-gated acquisition scan (MUGA) or echocardiogram
+Cardiac ejection fraction >= 45% by echocardiogram (ECHO)
+Left ventricular ejection fraction (LVEF) >= 45% by multi-gated acquisition scan (MUGA) or rest echocardiogram (ECHO)
+Left ventricular ejection fraction (LVEF) >= 50% by transthoracic echocardiogram or multigated acquisition scan (MUGA)
+Ejection fraction > 45% by either multi-gated acquisition scan (MUGA) scan or echocardiogram
+Patients have left ventricular ejection fraction (LVEF) >= 50% by multigated acquisition scan (MUGA) or echocardiogram before study randomization
+Baseline left ventricular ejection fraction of at least 40% by multigated acquisition (MUGA) or echocardiography (ECHO)
+Left ventricular ejection fraction (LVEF) at rest >= 40%; for patients aged < 13 years, shortening fraction (SF) >= 26% by echocardiogram or LVEF by multigated acquisition scan (MUGA) may be used
+Multi-gated acquisition (MUGA) scan or echocardiogram (ECHO) >= ejection fraction (EF) of 50%
+Shortening fraction > 28% by echocardiogram or
+Left ventricular ejection fraction >= 45%, assessed within 3 months prior to study day 0, e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure
+Baseline (pre-HCT) multi-gated acquisition (MUGA) or echocardiography (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of normal (LLN) of the institutional normal
+Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction >= 40%; for children that are not able to cooperate with multi-gated acquisition scan (MUGA) and echocardiography, such should be clearly stated in the physician’s note
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) of the institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration
+Left ventricular ejection fraction >= 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 6 months of study entry
+Left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition (MUGA) scan or electrocardiogram (ECHO), or uncontrolled hypertension (refer to World Health Organization-International Society of Hypertension [WHO-ISH] guidelines)
+Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) >= 35% as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA)
+Left ventricular ejection fraction (LVEF) >= 50% measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
+Left ventricular ejection fraction (LVEF) < 50 as determined by multi gated acquisition scan (MUGA) scan or echocardiography (ECHO)
+Multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) for left ventricular ejection fraction (LVEF) >= 45%
+Left ventricular ejection fraction >= 40% as confirmed by echocardiogram (ECHO)/multi gated acquisition scan (MUGA)
+Adequate cardiac function as defined by the following:\r\n* Left ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram\r\n* Corrected QT interval (QTc) interval =< 480 ms (preferably the mean from triplicate electrocardiogram [ECG’s])
+Cardiac function >= international lower limit of normal (ILLN), e.g., left ventricular ejection fraction (LVEF) of > 50% as assessed by multi gated acquisition scan (MUGA) or echocardiography (ECHO), corrected QT interval (QTc) < 470 ms
+Baseline multi-gated acquisition (MUGA) or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% within 6 weeks prior to initiation of neoadjuvant chemotherapy
+Left ventricle ejection fraction (LVEF) >= 40% confirmed by echocardiography (ECHO)/ multi gated acquisition scan (MUGA)
+Baseline multi gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%
+Ejection fraction (EF) >= 50% on multi gated acquisition (MUGA) scan or echocardiogram
+Left ventricular ejection fraction (LVEF) lower limit of normal (LLN) as assessed by either multigated acquisition (MUGA) scan or echocardiogram (ECHO)
+Has a shortening fraction of >27% or an ejection fraction of ?50% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan and New York Heart Association (NYHA) Class ?2
+Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
+Ejection fraction of > 40% by multigated acquisition (MUGA) or echocardiogram
+Left ventricular ejection fraction (by transthoracic echocardiography [TTE], multigated acquisition scan [MUGA] or cardiac magnetic resonance imaging [MRI]) sufficient to safely administer mitoxantrone as determined by the treating physician
+Baseline multi-gated acquisition (MUGA) scan or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% at least 6 weeks prior to initiation of NACT
+Ejection fraction measured by echocardiogram or multigated acquisition scan (MUGA) >= 50%
+Cardiac ejection fraction >= 40% (by either echocardiogram [ECHO] or multigated acquisition [MUGA])
+Cardiac ejection fraction >= 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
+If prior history of ischemic heart disease or exposure to 200 mg/m^2 of doxorubicin, patients must have a measured ejection fraction (either by multigated acquisition scan [MUGA], echocardiogram [ECHO], stress test, or ventriculography) of at least 45%
+Patients with a cardiac ejection fraction (as measured by either multi-gated acquisition [MUGA] scan or echocardiogram) < 40%; (Note: patients who have had prior anthracycline exposure of > 250 mg/m^2 may be eligible after discussion with the principal investigator [PI])
+For children with neuroblastoma (NBL): normal ejection fraction (> 55%) documented by echocardiogram or radionuclide multi-gated acquisition (MUGA) evaluation OR normal fractional shortening (> 27%) documented by echocardiogram; for subjects with paraganglioma/ pheochromocytoma: no clinically significant cardiac dysfunction
+Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) or magnetic resonance imaging (MRI) >= 40%
+Cardiac ejection fraction of >= 50% by echocardiogram or multi gated acquisition scan (MUGA)
+Patients must have normal cardiac function, as evidenced by a left ventricular ejection fraction (LVEF) within institutional normal limits; echocardiogram may be used if multi gated acquisition (MUGA) scan is not available, but the same test must be used throughout the study to evaluate LVEF
+Shortening fraction > 28% by echocardiogram or an ejection fraction > 50% by multigated acquisition scan (MUGA)
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (Echo) or multi gated acquisition scan (MUGA)
+Left ventricular ejection fraction (LVEF) >= 50% by echocardiogram (ECHO) or multi gated acquisition (MUGA) scan
+The left ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or multi-gated acquisition (MUGA) scan performed within 90 days prior to study entry must be greater than or equal to 50% regardless of the facility's lower limit of normal (LLN).
+Cardiac ejection fraction > 50% (for HER2+ patients) as assessed by echocardiogram, multigated acquisition (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
+Left ventricular ejection fraction (LVEF) of 50% or above, by multigated acquisition scan (MUGA) or echocardiogram
+Ejection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) >= 50%
+Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 45% (evaluation within 6 weeks of screening does not need to be repeated)
+Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
+If the research participant is to undergo leukapheresis, he/she must have ejection fraction measured by echocardiogram or multigated acquisition scan (MUGA) > 45% (within 6 weeks of time of screening)
+Cardiac ejection fraction >= 40% (by either cardiac echocardiogram [echo] or multi gated acquisition [MUGA] scan); documentation of recent (=< 6 months from screening) outside reports is acceptable
+Ejection fraction >=40% by transthoracic echocardiogram or radionuclide ventriculogram, i.e. multigated acquisition (MUGA) scan
+Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >= 50% AND no finding of abnormal wall motion (i.e. report does not indicate that wall motion is “abnormal” or “altered”)
+Left ventricular ejection fraction (LVEF) greater than or equal to 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram (Phase II only)
+Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
+Normal cardiac function as defined by a normal ejection fraction by multi gated acquisition scan (MUGA) or echocardiogram
+Adequate cardiac function (ejection fraction [EF] > 50%) based on multi gated acquisition (MUGA) scan or 2 dimensional-echocardiogram (2D-Echo)
+Left ventricle ejection fraction (LVEF) >= 40% confirmed by echocardiogram (ECHO)/multi gated acquisition (MUGA) scan
+Left ventricular ejection fraction (LVEF) >= 40%; 2-dimension (D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multi gated acquisition scan (MUGA) is acceptable if ECHO is not available
+Left ventricular ejection fraction (LVEF) >= 50% by MUGA (multi gated acquisition) scan or echocardiogram
+Patients must have adequate cardiac function (left ventricular ejection fraction [LVEF]) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram
+Patients must have normal baseline cardiac function based upon echocardiogram or gated blood pool scan (multigated acquisition scan [MUGA]) with an ejection fraction >= 50%
+Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
+Left ventricular ejection fraction (LVEF) =< 50% as documented by multi gated acquisition scan (MUGA) or echocardiogram performed within 28 days prior to the first study treatment
+Left ventricular ejection fraction (EF) > 40% by echocardiogram, multigated acquisition scan (MUGA), or cardiac magnetic resonance (MR)
+No cardiac (left ventricular ejection fraction [LVEF] > 50% by multigated acquisition scan [MUGA] or three-dimensional echocardiography [TTE]; if LVEF > 40% but < 50% by MUGA or TTE MUST HAVE cardiology evaluation and clearance for ASCT)
+Cardiac ejection fraction of >= 50% by echocardiogram or multi gated acquisition scan (MUGA)
+Left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) or other similar cardia imaging performed within 1 month of treatment
+Have a left ventricular ejection fraction (LVEF) >45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
+Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of 45% or greater, by multiple gated acquisition (MUGA) or echocardiogram; no ongoing cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart failure
+Patients must obtain a base line echocardiogram or multi gated acquisition scan (MUGA) and require the left ventricular ejection fraction to be within normal limits (or 50% or higher)
+Patients with a cardiac ejection fraction (as measured by either multigated acquisition scan [MUGA] or echocardiogram) < 40% are excluded
+Left ventricular ejection fraction (LVEF) > lower limit of normal (LLN) on multi gated acquisition scan (MUGA)
+Cardiac ejection fraction >= 50% by multiple gate acquisition (MUGA) scan and/or by echocardiogram
+Cardiac dysfunction documented by an ejection fraction less than the lower limit of the facility normal by multi-gated acquisition (MUGA) scan, or less than 50% by echocardiogram
+Shortening fraction > 25% by echocardiogram or ejection fraction above the institutional lower limit of normal by multi gated acquisition scan (MUGA)
+The patient must be free of symptoms of uncontrolled cardiac disease, and must not have compromised cardiac function detected by echocardiogram (ECHO) or by gated cardiac blood flow scan (multi gated acquisition scan [MUGA]) left ventricular ejection fraction [LVEF] > 45%)
+Shortening fraction of >= 27% by echocardiogram
+Multi gated acquisition scan (MUGA) > 45% injection fraction
+Adequate cardiac function (left ventricular ejection fraction [LVEF] >= 40%) as assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan performed within 1 month of treatment
+Left ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition scan (MUGA)/echocardiogram (ECHO)
+Cardiac: absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction >= 35%; for children that are not able to cooperate with multi gated acquisition scan (MUGA) and echocardiography, such should be clearly stated in the physician’s note
+No active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if multi gated acquisition (MUGA) is obtained, the left ventricular ejection fraction (LVEF) should exceed 40%
+Left ventricular ejection fraction ? 50% by echocardiogram or multiple gated acquisition scan.
+Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 45%; for children not able to cooperate with multigated acquisition (MUGA) or echocardiography, such should be clearly stated in the physician’s documentation
+Cardiac ejection fraction (LVEF) by multiple gated acquisition scan (MUGA) less than the institutional lower limit of normal.
+Patients must have a baseline left ventricular ejection fraction (LVEF) measured by multi-gated acquisition scan (MUGA) equal to or greater than the lower limit of normal for the radiology facility and if there are two consecutive MUGAS performed while on trastuzumab from the same radiology facility, there cannot be a decrease in LVEF of > 15% from the original MUGA scan
+Left ventricular ejection fraction (LVEF) assessment must be performed within 6 weeks prior to randomization; (LVEF assessment performed by echocardiogram is preferred; however, multigated acquisition scan (MUGA) scan may be substituted based on institutional preferences); the LVEF must be >= 55% regardless of the cardiac imaging facility's lower limit of normal
+Left ventricular ejection fraction ? 45%, assessed within 12 months prior to study day 0, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure
+Left ventricular ejection fraction (LVEF) >= 50% measured by multigated acquisition (MUGA) scan, echo, or stress test study with myocardial perfusion imaging
+Left ventricular ejection fraction (LVEF) >= 45% as determined by a multigated acquisition (MUGA) scan or echocardiogram, and QTc interval =< 480ms
+Normal ejection fraction (>= 55%) documented by either echocardiogram or radionuclide MUGA evaluation OR normal fractional shortening (>= 27%) documented by echocardiogram
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition (MUGA)
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 3 weeks prior to starting study therapy
+Left ventricular ejection fraction (LVEF) >= 45% at rest (multi gated acquisition [MUGA] or echocardiogram [ECHO])
+To be performed within 28 days prior to day 1 of protocol therapy: Left ventricular ejection fraction >= 50% as determined by multigated acquisition (MUGA) scan or echocardiogram
+Left ventricular ejection fraction (LVEF) >= 50% calculated by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
+Cardiac ejection fraction >= 45% or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a two-dimensional (2-D) echocardiogram (ECHO) scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to receiving treatment\r\n* NOTE: when a multi gated acquisition scan (MUGA) or echocardiogram cannot be obtained due to weekend or holiday, then patients may be enrolled provided there is no history of significant cardiovascular disease and a measurement of cardiac ejection fraction will be performed within 5 days of study enrollment
+Shortening fraction of >= 27% by echocardiogram, or
+Left ventricular ejection fraction (LVEF) assessment (eg, echocardiogram, radionuclide ventriculogram scan [MUGA], first-pass technique) performed within 3 months prior to initiation of study treatment indicates an LVEF of >= 50%
+Ejection fraction (EF) >= 50% by multigated acquisition (MUGA) or echocardiography (ECHO) within 4 weeks prior to first dose of study treatment
+Left ventricular systolic dysfunction, defined as ejection fraction below institutional normal by echocardiography or multi-gated acquisition scan (MUGA); or current or past clinical diagnosis of congestive heart failure; history of ejection fraction decreased to below institutional normal or decrease of greater than 15% attributable to past trastuzumab or pertuzumab therapy
+Adequate cardiac function:\r\n* Left ventricular ejection fraction (LVEF) >= 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (echo)\r\n* Corrected QT (QTc) interval =< 480 ms
+Left ventricular ejection fraction (EF) > 40% by echocardiogram, multi-gated acquisition (MUGA), or cardiac magnetic resonance (MR)
+Left ventricular ejection fraction (LVEF) < 40% as measured by echocardiogram or multi gated acquisition scan (MUGA)
+Shortening fraction of >= 27% by echocardiogram, or
+Left ventricular ejection fraction (LVEF) >= 45% at rest (multigated acquisition scan [MUGA] or echocardiogram [Echo])
+Cardiac function:\r\n* Normal ejection fraction (>= 55%) documented by either echocardiogram or radionuclide multi gated acquisition scan (MUGA) evaluation; OR \r\n* Normal fractional shortening (>= 27%) documented by echocardiogram
+Left ventricular ejection fraction (LVEF) > 40% as assessed by echocardiogram or multi gated acquisition scan (MUGA)
+Shortening fraction >= 27% by echocardiogram, or
+Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) documented within four weeks prior to first dose of study drug; adequate cardiac reserve ejection fraction (EF) >= 50%
+Patients must have multigated acquisition (MUGA)/echocardiogram performed within 28 days prior to sub-study registration
+Left ventricular ejection fraction (LVEF) >= 0.4 by multi gated acquisition scan (MUGA) or echocardiogram
+Left ventricular ejection fraction (LVEF) =< 55% as determined by multi gated acquisition (MUGA) scan or echocardiogram (ECHO)
+Left ventricular ejection fraction (LVEF) >= 50% at baseline as determined by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
+Ejection fraction (EF) measured by two-dimensional echocardiogram (2D-ECHO) or multigated acquisition scan (MUGA) scan of >= 45%
+Echocardiogram or multi gated acquisition (MUGA) scan demonstrating an ejection fraction >= 45%
+Baseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 45%
+Left ventricular ejection fraction (LVEF) >= 50% by echocardiogram (ECHO) or multigated acquisition scan (MUGA); same method as used at baseline must be use throughout the study, ECHO is the preferred method
+Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional [2-D] echocardiogram is preferred; however, multi gated acquisition scan [MUGA] scan may be substituted based on institutional preferences); the LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal; note: since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments, it is critical that this baseline study be an accurate assessment; if the baseline LVEF is > 65%, the investigator is encouraged to have the accuracy of the initial LVEF result confirmed and repeat the test if the accuracy is uncertain
+Baseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (multi gated acquisition scan [MUGA] scan) or echocardiogram
+Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
+Left ventricular ejection fraction (LVEF) greater than or equal to institutional/laboratory lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
+Patients must have either echocardiogram (ECHO) with ejection fraction >= 45% within 28 days prior to registration
+Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multigated acquisition (MUGA) > 40%
+Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 50%
+Adequate cardiac function as defined by either of the following:            \r\n* An echocardiogram demonstrating an ejection fraction within normal limits\r\n* A multi gated acquisition (MUGA) scan demonstrating an ejection fraction within normal limits
+Cardiac function: left ventricular ejection fraction >= 40% by multi gated acquisition scan (MUGA) or cardiac magnetic resonance imaging (MRI), or fractional shortening >= 28% by echocardiogram (ECHO)or left ventricular ejection fraction >= 50% by ECHO
+Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) (by echocardiogram [ECHO] or multi gated acquisition scan [MUGA])
+Ejection fraction (EF) by multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiogram within institution normal limits; in case of low EF, the subject may remain eligible after a stress echocardiogram is performed if the EF is more than 35% and if the increase in EF with stress is estimated at 10% or more
+Patients must have a cardiac ejection fraction > 45% on two-dimensional (2D) echocardiography or multi gated acquisition scan (MUGA) obtained within 28 days of study enrollment
+Left ventricular ejection fraction >= 45% by multigated acquisition scan (MUGA) or echocardiogram (ECHO), fractional shortening >= 28% by ECHO
+Ejection fraction (EF) by multiple gated acquisition scan (MUGA) or 2-dimensional (D) echocardiogram within institution normal limits; in case of low EF, the subject may remain eligible after a stress echocardiogram is performed if the EF is more than 35% and if the increase in EF with stress is estimated at 10% or more
+Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by cardiac echocardiogram (echo) or multi gated acquisition (MUGA) scan within 56 days prior to step 2 registration
+Left ventricular ejection fraction (LVEF) that is at or above the lower institutional limits of normal, as assessed by multiple gated acquisition (MUGA) scan or echocardiogram within the 6 weeks prior to registration
+Left ventricular ejection fraction at or above institutional lower limit of normal (obtained within 8 weeks of registration by multigated acquisition [MUGA] scan or echocardiogram; the same test performed at baseline should be repeated after every 3 cycles of therapy)
+American Heart Association class I: patients with cardiac disease but without resulting limitation of physical activity; ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain; additionally, patients > 60 years of age must have a left ventricular ejection fraction of at least >= 40% demonstrated by multi gated acquisition scan (MUGA) or echocardiogram (Echo)
+Left ventricular ejection fraction (LVEF) >= 45%, preferably by 2-dimensional (D) echocardiogram (echo), or by multiple gated acquisition scan (MUGA); however, patients with LVEF of between 35% and 44% may also be eligible provided that such patients are cleared by a cardiology consultation; in such cases, cardiology will determine whether it is appropriate to perform a cardiac stress test
+Left ventricular ejection fraction (LVEF) > 40% (multi gated acquisition scan [MUGA] or echocardiogram) normal per institutional standard
+Poor cardiac function: left ventricular ejection fraction < 50% as determined by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) or a shortening fraction below 27%
+Has a shortening fraction of >27% or an ejection fraction of ?50% by echocardiogram or multi-gated acquisition scan
+Patients must have a left ventricular ejection fraction (LVEF) >= 50% by echocardiogram or multiple gated acquisition (MUGA) scan within 42 days prior to registration
+Patients must not have presence of class III or IV heart failure, according to New York Heart Association classifications, or a known left ventricular ejection fraction of less than 50%; Note: left ventricular ejection fraction (LVEF) evaluation by echocardiogram or multi-gated acquisition scan (MUGA) is not required prior to registration
+Patients must have a cardiac ejection fraction >= institutional lower limit of normal (ILLN) by multi gated acquisition (MUGA) scan or 2-dimensional (D) echocardiogram (ECHO) within 42 days prior to registration
+Cardiac ejection fraction at or above the lower limit of normal as measured by multigated radionuclide angiography (MUGA) scans or echocardiogram documented =< 3 months prior to registration
+Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] <40% and shortening fraction <15%). Appropriate correction to be used, if a MUGA is performed.
+CLINICAL/LABORATORY CRITERIA: Patients must have a left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) by echocardiography (ECHO) or multi-gated acquisition scan (MUGA) within 42 days prior to registration
+Hemodynamically stable and Left Ventricle Ejection Fraction (LVEF) ? 45% confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA)
+Abnormal left ventricular ejection fraction (LVEF; <50%) or echocardiogram ECHO or multiple gated acquisition scan (MUGA). [Applies to Phase 1 only; ECHO/MUGA scans are not performed in Phase 2.]
+Left ventricular ejection fraction < 50% on echocardiogram or multi-gated acquisition (MUGA)
+Left ventricular ejection fraction (LVEF) ?50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
+Left ventricular ejection fraction (LVEF) ? 40% as measured by MUGA scan or 2-D ECHO within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead ECG
+Left ventricular ejection fraction (LVEF) ? 40% as measured by MUGA scan or 2-D ECHO within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead ECG
+Patients must have a left ventricular ejection fraction >= lower limit of normal by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
+Left Ventricular Shortening Fraction (LVSF) ? 28% confirmed by echocardiogram (ECHO), or Left Ventricular Ejection Fraction (LVEF) ? 45% confirmed by echocardiogram or Multiple Uptake Gated Acquisition (MUGA).
+Have left ventricular ejection fraction by multigated acquisition scan (MUGA) scan or 2D-ECHO within normal limits for the institution
+Patients with a known history of congestive heart failure or cardiac ejection fraction < 50% (or less than institutional normal limits); echocardiogram (ECHO) or multigated acquisition scan (MUGA) is not required prior to enrollment; for patients assigned to the chemotherapy arm, an ECHO or MUGA should be done within 6 months of day 1 of gemcitabine-docetaxel treatment\r\n* Patients who enroll on study and are randomized to Regimen I (chemotherapy ) and then are found on baseline ECHO or MUGA to have cardiac ejection fraction < 50% or below institutional normal will remain ON study; such patients will receive gemcitabine + docetaxel for 4 cycles but will NOT receive any doxorubicin treatment; they will continue treatment follow-up as outlined for all patients assigned to Regimen I
+Left ventricular ejection fraction >= lower limit of normal as assessed by echocardiogram or multigated acquisition scan
+Patients who received prior therapy with anthracyclines should have a baseline multigated acquisition scan (MUGA) or echocardiogram (echo) with a normal ejection fraction within 28 days prior to randomization
+Ejection fraction of >= 45% by either multi-gated acquisition (MUGA) scan or echocardiogram (ECHO)
+Has a pre-study echocardiogram or multi-gated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institutional lower limit of normal within one month of initiating therapy.
+Left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Gated acquisition scan (MUGA) or echocardiogram (ECHO)
+Left ventricular ejection fraction (LVEF) must be equal to or greater than 50%, as measured by multi gated acquisition (MUGA) scan or echocardiogram
+left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiography (ECHO).
+Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).
+Left ventricular ejection fraction (LVEF) greater than 50% on echocardiography or multiple gated acquisition (MUGA) scan.
+Patient has a Left Ventricular Ejection Fraction (LVEF) < 50 % as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening
+For participants who will be receiving CHOP: left ventricular ejection fraction (LVEF) <50% by multiple-gated acquisition (MUGA) scan or echocardiogram
+Patients must have a left ventricular ejection fraction (LVEF) >= 50% by (either multigated acquisition [MUGA] or 2-dimensional [2-D] echocardiogram) within 28 days of registration
+Subjects with major cardiac illness multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) < 50% ejection fraction (EF)
+Cardiac ejection fraction >= 50% by echocardiography or multi gated acquisition (MUGA) (when left ventricular ejection fraction [LVEF] expressed as a range, at least the upper limit should include 50%)
+Baseline multi gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%
+Left ventricular ejection fraction (LVEF) >= 40% as confirmed by echocardiogram (ECHO)/multigated acquisition (MUGA)
+Patient must have adequate cardiac function (left ventricular ejection fraction [LVEF] >= 50% as determined by a multigated acquisition [MUGA] scan or echocardiogram; and corrected QT [QTc] interval =< 480 ms by Fridericia’s formula [QTcF])
+Cardiac left ventricular function with resting ejection fraction >50% as determined by echocardiogram (ECHO) or multigated acquisition scan (MUGA).
+Baseline Left Ventricular Ejection Fraction (LVEF) >/= 55 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA)
+Subjects with multi gated acquisition scan (MUGA) < 50% ejection fraction (EF)
+Left ventricular ejection fraction less than (<) 50% as defined by multiple-gated acquisition (MUGA)
+Shortening fraction of >= 27% by echocardiogram (ECHO) OR
+Ejection fraction >= 50% by ECHO or gated radionuclide study
+Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 55 percent (%) measured by echocardiogram (ECHO) or Multiple-Gated Acquisition (MUGA) Scan
+Shortening fraction >= 27% by echocardiogram
+Ejection fraction >= 47% by radionuclide angiogram (multi gated acquisition scan [MUGA]); Note: the echocardiogram (or MUGA) may be done within 28 days prior to enrollment
+Left ventricular ejection fraction (LVEF) >= 50% as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented =< 28 days prior to registration
+Baseline left ventricular ejection fraction LVEF >= 50% as evaluated by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
+Patients older than 70 years of age should have left ventricular ejection fraction within ULN by multigated acquisition (MUGA) or 2-dimensional (2D) echocardiogram
+Left ventricular ejection fraction > 45% by either multi gated acquisition scan (MUGA) scan or echocardiogram; if ejection fraction (EF) is < 50%, a cardiology consult should be placed and echocardiogram performed if not already done
+Left ventricular ejection fraction (LVEF) < 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram
+Left ventricular ejection fraction (LVEF) defined by multigated acquisition (MUGA) or echocardiogram which is below the institutional lower limit of normal prior to starting study treatment
+Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 55%); appropriate correction to be used if a MUGA is performed
+Has a left ventricular ejection fraction (LVEF) within the normal institutional range (or >= 50%) based on an echocardiogram (ECHO) or multigated acquisition scan (MUGA), completed within 4 weeks prior to day one of treatment
+Ejection fraction of < 45% by either multi gated acquisition scan (MUGA) or echocardiogram (ECHO)
+For patients in stratum A, an echocardiogram (ECHO) or multi gated acquisition scan (MUGA) demonstrating ejection fraction (EF) > 50% is required within 28 days prior to study drug administration
+Baseline ejection fraction ? 50% as assessed by echocardiogram or MUGA.
+Left ventricular ejection fraction of >= 40% by multi-gated acquisition (MUGA) scan or echocardiogram
+Baseline ejection fraction >= 50% by multi gated acquisition scan (MUGA) scan or echocardiogram performed =< 60 days prior to registration
+Left ventricular ejection fraction (LVEF) must be equal to or greater than 40%, as measured by multi gated acquisition (MUGA) scan or echocardiogram
+Intraventricular septal (IVS) thickness =< 25 mm (as determined by 2-dimensional [2D] echocardiography or cardiac magnetic resonance imaging [MRI]) (ejection fraction may also be assessed by a multi-gated acquisition [MUGA])
+Baseline Left ventricular ejection fraction (LVEF) >=50% as measured by Echocardiogram (ECHO) or Multigated acquisition (MUGA) and above the testing institution's lower limit of normal
+Patients who have abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 50%); appropriate correction to be used if a MUGA is performed
+Must have an echocardiogram or multi gated acquisition scan (MUGA) indicating left ventricular ejection fraction (LVEF) >= 50% within 42 days prior to first dose of study drug
+Left ventricular ejection fraction (LVEF) no more than 5 absolute percentage points below the institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration (i.e., if the institutional normal is 50%, subject's LVEF may be as low as 45% to be eligible for the study)
+Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1.
+Left ventricular ejection fraction (LVEF) >= 40% on 2-dimentional (2-D) transthoracic echocardiogram (ECHO); multigated acquisition scan (MUGA) is acceptable
+Subjects must have a multi gated acquisition scan (MUGA) and/or echocardiogram (ECHO) or cardiac magnetic resonance (MR); the required minimum standards include MUGA or ECHO or cardiac MR showing an ejection fraction (EF) of 40%; those with an EF 40-49% must also have a cardiologist consult and assist with management
+Adequate cardiac function defined as left ventricular ejection fraction (LVEF) >= 40%\r\n* NOTE: 2-dimensional (2-D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation\r\n* Multigated acquisition scan (MUGA) is acceptable if ECHO is not available
+Cardiac ejection fraction >= 45% by echocardiography (transthoracic echocardiography) or multi gated acquisition scan (MUGA) scan
+Left ventricular ejection fraction (LVEF) of at least 50% as determined by MUGA or echocardiogram
+Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower, as determined by echocardiogram or Multi Gated Acquisition Scan (MUGA) scan
+Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram or multigated acquisition scan (MUGA) documented within 4 weeks prior to first dose of study drug.
+Baseline left ventricular ejection fraction (LVEF) >/=55% measured by echocardiogram (ECHO; preferred) or multiple-gated acquisition (MUGA) scans
+Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
+Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
+Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
+Left ventricular ejection fraction (LVEF) >= 50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
+Have a 12-lead electrocardiogram (ECG) and echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed by the investigator or other qualified person to evaluate cardiac function prior to enrollment in the study
+Adequate cardiac function, defined as left ventricular ejection fraction ? 40% as assessed by echocardiogram or multiple uptake gated acquisition scan performed within 30 days prior to determination of eligibility
+Left ventricular ejection fraction >= 50%, as determined by radionuclide ventriculogram (RVG) (multigated acquisition [MUGA]) or echocardiogram (ECHO) within 60 days prior to initiation of protocol therapy
+Patients must have adequate cardiac function as demonstrated by normal left ventricular ejection fraction (LVEF) >= the lower limit of normal for the facility on multi gated acquisition (MUGA) scan or echocardiogram (ECHO) within 3 months of enrollment
+Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1.
+Left ventricular ejection fraction (LVEF) >= 50%, as determined by radionucleoventilugrams (RVG) (multi-gated acquisition-MUGA) or echocardiogram (ECHO) within 28 days prior to initiation of protocol therapy
+Patient must have a left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition (MUGA) within 28 days prior to registration
+Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
+Left ventricular ejection fraction (LVEF) greater or equal to 50% at baseline as determined by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA), or within the institution’s normal limits
+Left ventricular ejection fraction within institutional normal limits, as determined by echocardiography or multiple uptake gated acquisition (MUGA) scan
+Normal left ventricular ejection fraction on multigated acquisition scan (MUGA) or echocardiogram within the past 1 year prior to registration for patients with history of congestive heart failure and/or coronary disease requiring medications other than aspirin, or known prior exposure to anthracycline chemotherapy
+Ejection fraction by echocardiogram (ECHO) or multigated acquisition scan (MUGA) of >= 40% performed
+Echocardiogram (Echo) or multi-gated acquisition scan (MUGA) with ejection fraction > 50%
+Ejection fraction on echocardiogram (Echo) or multi gated acquisition scan (MUGA) > 50%
+Adequate cardiac function (left ventricular ejection fraction [LVEF] > 40%) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed within 1 month of treatment
+Ejection fraction >= 45% as determined by transthoracic echocardiogram or multigated acquisition scan (MUGA)
+Cardiac ejection fraction >= lower limit of normal as determined by 2-dimensional (D) echocardiogram (echo) or multigated acquisition (MUGA) scan according to institutional standards
+Cardiac ejection fraction, as assessed by either multigated acquisition (MUGA) scan or echocardiogram, greater than or equal to 50%, within 28 days prior to registration
+Screening Left ventricular ejection fraction (LVEF) >/= 50% on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) after receiving neoadjuvant chemotherapy and no decrease in LVEF by more than 15% absolute points from the pre-chemotherapy LVEF. Or, if pre-chemotherapy LVEF was not assessed, the screening LVEF must be >/= 55% after completion of neoadjuvant chemotherapy.
+An echocardiogram (ECHO) or multiple gated acquisition (MUGA) demonstrating ejection fraction (EF) > 50%
+Left ventricular ejection fraction (LVEF) >= 50% by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)\r\n* Same method as used at baseline must be use throughout the study, ECHO is the preferred method
+Cardiac ejection fraction ? 50% by echocardiography or MUGA
+Subjects with an evaluation of cardiac function indicating normal function on MUGA scan (multiple gated acquisition scan) or other methodology; AND
+Left ventricular ejection fraction (LVEF) must be >= the lower limit of normal (LLN) per institutional standards by either echocardiography or radionuclide-based multiple gated acquisition (MUGA)
+Left ventricular ejection fraction (LVEF) by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) >= 45%
+Normal cardiac function defined as either a MUGA or echocardiogram (ECHO) with left ventricular ejection fraction (LVEF) in normal institutional range (MUGA 50%; ECHO 55%)
+Shortening fraction >= 28% on screening echocardiogram
+Left ventricular ejection fraction >= 50%, as determined by radionuclide ventriculograms (RVG) (multi-gated acquisition scan [MUGA]) or echocardiogram within 60 days prior to initiation of protocol therapy
+Left ventricular ejection fraction >= 50%, as determined by RVG (MUGA) or echocardiogram within 60 days prior to initiation of extension phase therapy (all cohorts)
+Patients must have a multi gated acquisition scan (MUGA) or echocardiogram within 90 days prior to starting treatment and the ejection fraction must be >= 45%
+Left ventricular ejection fraction estimated by multi gated acquisition scan (MUGA) scan or 2-dimensional (2D)-echocardiogram of at least 45% cardiology consult is recommended prior to enrollment if a history of coronary artery disease, congestive heart failure (CHF) with estimated left ventricular ejection fraction (LVEF) of < 50% or clinically significant arrhythmia
+Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 50%
+Left ventricular ejection fraction (LVEF) >= 45% at rest (multi gated acquisition [MUGA] or echocardiogram [Echo])
+Impaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by echocardiogram (ECHO) or multi gated acquisition (MUGA) scan
+Normal cardiac function as demonstrated by a left ventricular ejection fraction >= 50% on echocardiogram or multi gated acquisition (MUGA) scan
+Ejection fraction < 50%, as determined by echocardiogram or multi gated acquisition scan (MUGA)
+Left ventricular ejection fraction (LVEF) < institutional lower limit of normal (LLN) by ECHO (preferred) or MUGA scan at the time of transition to this study.
+Left ventricle ejection fraction (LVEF) >= 40%; 2-dimensional (D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated acquisition scan (MUGA) is acceptable if ECHO is not available
+Left ventricular ejection fraction >= 50% OR shortening fraction of >= 27% demonstrated on 2 dimensional (2D) echocardiogram or multi gated acquisition scan (MUGA)
+For participants who will be receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP): left ventricular ejection fraction (LVEF) less than (<) 50% by multiple-gated acquisition (MUGA) scan or echocardiogram
+Adequate cardiac function, defined by baseline LVEF greater than 50% by Multiple Gated Acquisition (MUGA) scan or echocardiogram.
+Left ventricular ejection fraction assessment (echocardiogram or multiple gated acquisition [MUGA] scan) performed within 4 weeks prior to study initiation, showing a left ventricular ejection fraction (LVEF) value >= lower limit of normal (LLN)
+Multiple Gated Acquisition (MUGA) or echocardiogram (ECHO) must demonstrate LVEF >/= 45%.
+Left ventricular ejection fraction >= 50% by echocardiogram (ECHO) or multi-gated acquisition scan (MUGA)
+Left ventricular ejection fraction measured by multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) >= 45%
+Cardiac ejection fraction >= 50% as measured by echocardiogram of multiple gated acquisition scan (MUGA) scan
+Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
+Left ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium-99m pertechnetate radionuclide cineangiography (multi gated acquisition scan [MUGA]) or echocardiogram
+Subjects must have a MUGA scan or echo with LVEF >50%
+Left ventricular ejection fraction >= the lower limit of normal by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
+Left ventricular ejection fraction (LVEF) >= 50% (as assessed by echocardiography [ECHO] or multigated acquisition [MUGA]) documented within 4 weeks prior to first dose of study treatment
+Left ventricular ejection fraction (LVEF) >= 40% within 28 days prior to registration, evaluated by 2-dimensional (D) transthoracic echocardiogram (ECHO) or, if ECHO is not available, by multi-gated acquisition (MUGA) scan
+History of significant cardiovascular disease, even if currently controlled, or who has signs or symptoms suggesting impaired left ventricular function in the judgment of the investigator must have a screening left ventricular ejection fraction (LVEF) evaluation by echocardiogram (ECHO) or multi gated acquisition scan (MUGA); patients with LVEF measurements below local institutional lower limit of normal or less than 50% will not be eligible
+Adequate cardiac function (left ventricular ejection fraction [LVEF] >= 40%) as assessed by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) or other similar cardiac imaging performed within 1 month of enrollment
+Ejection fraction (EF) > 50% by multi gated acquisition scan (MUGA)
+Eligible for SCT with left ventricular ejection fraction (LVEF) >= 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO), and diffusing capacity > 50% predicted by pulmonary function testing
+Left ventricular ejection fraction > 45% by either multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiogram (echo), obtained within 28 days of enrollment; patients who have a prior cumulative anthracycline dose greater than 450 mg/m^2 will also have a cardiology consult to determine if further anthracycline administration is an absolute contraindication in patients who may require induction chemotherapy with EPOCH-F
+Patients must have an echocardiogram or multi gated acquisition (MUGA) scan; if the ejection fraction is < 40%, the patient will not be eligible; if the ejection fraction is 40-50%, patients must have an exercise echocardiogram or dobutamine-echocardiogram (echo) with a normal response to exercise
+Cardiac ejection fraction (EF) < 40% on multi-gated acquisition (MUGA) scan or cardiac echocardiogram (echo) (or if unable to obtain ejection fraction, shortening fraction of < 26%); patients with active or a history of cardiac disease should be evaluated with appropriate cardiac studies and/or consult; ejection fraction is required if age > 50 years or there is a history of anthracyclines or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
+Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) AND at least 50%; LVEF can be assessed by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
+LVEF < 45% by echocardiogram
+Ejection fraction (EF) of at least >= 40% by multigated acquisition (MUGA) or echocardiography (ECHO)
+Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram or multi-gated acquisition scan (MUGA)
+LVEF (left ventricular ejection fraction) of 45% or less as determined by MUGA (multi-gated acquisition) or ECHO (Echocardiogram)
+Normal cardiac left ventricular ejection fraction (LVEF) by multiple-gated acquisition (MUGA) scan or transthoracic echocardiogram
+Cardiac ejection fraction >= 50% by multi-gated acquisition (MUGA) scan and/or by echocardiogram
+Adequate left ventricular function with ejection fraction >= 40% by echocardiogram or multi-gated acquisition scan (MUGA) scan
+Left ventricular ejection fraction (LVEF) by echocardiogram or multiple gated acquisition (MUGA) scan ? the lower limit of normal (LLN) for the Institution
+Patients have impaired cardiac function or clinically significant cardiac diseases, including any of the following: a) history or presence of serious uncontrolled ventricular arrhythmias or presence of atrial fibrillation; b) clinically significant resting bradycardia (< 50 beats per minute); c) left ventricular ejection fraction (LVEF) assessed by 2-dimensional (D) echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) < 45%; d) pericardial effusion
+Adequate cardiac function (left ventricular ejection fraction [LVEF] ?50% measured by echocardiography or multi-gated acquisition [MUGA] scan)
+Left ventricular ejection fraction (LVEF) within institutional range of normal as measured by echocardiogram (ECHO); multigated acquisition (MUGA) scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive (LVEF of > 50% required if normal range LVEF is not provided by institution)
+Baseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram
+Left ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram
+Left ventricular ejection fraction (LVEF) < 45% as determined by MUGA scan or ECHO
+Patients with a cardiac ejection fraction (as measured by either multi gated acquisition scan [MUGA] or echocardiogram) less than 40%
+Measured cardiac ejection fraction > or = to 50% or the institutional lower limit of normal by echocardiogram or MUGA scan.
+Cardiac ejection fraction >= 40% (multigated acquisition [MUGA] or echocardiogram); for patients with significant risk factors for coronary artery disease (CAD) (including family history, hypertension, and/or dyslipidemia), or age > 50, stress echo or stress thallium testing is required
+Normal (greater than 50%) left ventricular ejection fraction (LVEF) by multi gated acquisition (MUGA) scan or echocardiography
+Baseline left ventricular ejection fraction (LVEF) less than (<) 50%, documented by echocardiography, multiple-gated radionuclide angiography (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
+Left ventricular ejection fraction by multigated acquisition scan (MUGA) or echocardiogram >= 55% for patients with triple negative breast cancer; >= upper limit of institutional normal for patient with HR+ breast cancer within 7 days of treatment initiation
+Left ventricular ejection fraction =< 50% as demonstrated by echocardiogram or multigated acquisition scan (MUGA)
+Patients with left ventricular ejection fraction < 50% on echocardiogram or multigated acquisition scan will be excluded
+Left ventricular ejection fraction (LVEF) < 45% as determined by MUGA scan or echocardiogram (ECHO).
+Left ventricular ejection fraction (LVEF) >= 45 % (by multigated acquisition scan [MUGA] or echocardiography)
+Baseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 50%
+Left ventricular ejection fraction >= 45% by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
+Ejection fraction by multi gated acquisition scan (MUGA) scan or echocardiogram >= lower limit of institutional normal
+Left Ventricular Ejection Fraction (LVEF) < 40% as determined by Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO).
+Normal left ventricular ejection fraction on screening assessed by transthoracic echocardiogram or multiple gated acquisition (MUGA) scan
+Shortening fraction of >= 27% by echocardiogram, or
+Left ventricular ejection fraction (LVEF) determined by 2 dimensional echocardiogram (2D Echo) or multi-gated acquisition scan (MUGA) ? 50% or ? local institutional lower limit normal (LLN) whichever is higher.
+Cardiac ejection fraction >= 40% (by either cardiac echocardiogram [echo] or multigated acquisition [MUGA] scan); documentation of recent (=< 6 months from screening) outside reports is acceptable
+Baseline of Left Ventricular Ejection Fraction (LVEF) ?50% measured by echocardiography (ECHO) or multi-gated acquisition scan (MUGA)
+Adequate organ function defined by the screening laboratory inclusion listed below and Left Ventricular Ejection Fraction (LVEF) ? 45% confirmed by ECHO or multigated acquisition (MUGA)
+Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
+Patients with a left ventricular cardiac ejection fraction < 50% as assessed by an echocardiogram or MUGA scan
+Left ventricular ejection fraction (LVEF) >= 40% (multigated acquisition scan [MUGA] or echocardiogram)
+Left ventricular ejection fraction as measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) should be >= 40%
+All patients must have an echo or multigated acquisition (MUGA) scan showing ejection fraction (EF) > 50% and normal troponin and creatine kinase MB (CK MB) performed within 90 days of starting treatment
+Cardiac ejection fraction >= 50%, as measured by echocardiography (ECHO) or multigated acquisition scan (MUGA)
+Baseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (multi gated acquisition scan [MUGA] scan) or echocardiogram
+Cardiac ejection fraction ?50% by ECHO or MUGA
+Cardiac Function: Patient must have a shortening fraction (SF) of > 27% or an ejection fraction (EF) of > 50% by echocardiogram or MUGA scan.
+Shortening fraction of >= 27% by echocardiogram
+Left ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram
+Subjects with a left ventricular cardiac ejection fraction < 50% as assessed by an echocardiogram or MUGA scan
+Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
+Symptomatic left ventricular dysfunction or baseline left ventricular ejection fraction (LVEF) by multigated acquisition scan (MUGA) or echocardiogram (ECHO) =< 50% lower limit of institutional normal (LLN)
+Left ventricular ejection fraction (LVEF) > 40% (by echocardiogram [ECHO] or multigated acquisition scan [MUGA])
+Left ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition (MUGA) scan or echocardiogram (ECHO)
+Cardiac ejection fraction (EF) >= 45% by 2-dimensional echocardiogram (2D-Echo)
+Adequate cardiac function with LVEF >=50% as assessed by echocardiogram (ECHO) or Multi Gated Acquisition Scan (MUGA.
+Left ventricular ejection fraction (LVEF) >= 50% by either echocardiogram (ECHO) or multigated acquisition scan (MUGA)
+Screening calculated ejection fraction greater than or equal to the institutional lower limit of normal by multiple gated acquisition (MUGA) scan or by echocardiogram (ECHO); a MUGA is preferred because of greater reproducibility
+Left ventricular ejection fraction (LVEF) >= 40%, assessed within 28 days prior to registration, e.g. by multi gated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality
+Patients must have either echocardiogram (ECHO) or multi gated acquisition scan (MUGA) with ejection fraction >= 45% within 28 days prior to registration
+Cardiac ejection fraction · 40% (by either cardiac echocardiogram [ECHO] or multi gated acquisition [MUGA] scan)
+Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition scan (MUGA) or echocardiogram (ECHO).
+Left ventricular ejection fraction (LVEF) >= 40% within 30 days before cycle 1 day 1; 2-dimensional (2-D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated acquisition (MUGA) is acceptable if ECHO is not available
+Left ventricular ejection fraction (LVEF) less than 50 percent as assessed by echocardiography (or multi-gated acquisition) performed at screening
+Patients must have a pre-study echocardiogram or multigated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institution lower limit of normal within one month prior to start of study.
+Left ventricular ejection fraction (LVEF) ?institutional lower limit of normal as measured by multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiography (ECHO) within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead electrocardiogram (ECG)
+Left ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium-99m pertechnetate radionuclide cineangiography (multi gate acquisition scan [MUGA]) or echocardiogram
+All patients must have an left ventricular ejection fraction (LVEF) measurement of at least 50% by echocardiogram (ECHO) or multigated acquisition scan (MUGA) (if clinically indicated) within 14 days prior to registration; the method used for LVEF assessment in an individual subject must be the same throughout the trial
+Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
+LVEF (measured by Echocardiogram) > 50%
+Baseline multi gated acquisition (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 45%
+LVEF <45% as determined by MUGA or echo
+Normal (greater than 50%) left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan or echocardiography
+Shortening fraction >= 27% by echocardiogram or
+Baseline multiple gated acquisition (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 50%
+Patients with prior anthracycline exposure must have a baseline multi gated acquisition scan (MUGA) or echocardiogram prior to study entry
+Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) as assessed by echocardiography or multigated acquisition (MUGA) scan
+Normal cardiac function (ejection fraction >= lower limit of normal) as determined by multi-gated acquisition scan (MUGA) or echocardiogram
+Left ventricular ejection fraction > 40% (multi gated acquisition scan [MUGA] or echocardiogram [echo]) within 28 days of enrollment
+Shortening fraction of >= 25% by echocardiogram
+Left ventricular ejection fraction (LVEF) >= 50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with R-CHOP
+Cardiac left ventricular ejection fraction > 40% by echocardiogram or multi gated acquisition scan (MUGA)
+Shortening fraction of >= 27% by echocardiogram, or if shortening fraction abnormal, ejection fraction of >= 55% by gated radionuclide study or echocardiogram; note: the echocardiogram or gated radionuclide study must be performed within 4 weeks prior to enrollment
+Cardiac ejection fraction ?50% by ECHO or MUGA
+Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
+Left ventricular ejection fraction (LVEF) be at least >= institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration
+Left ventricular ejection fraction > 50% on echocardiography or multigated acquisition (ECHO/MUGA) scan
+Left ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram (ECHO)
+All patients must have an echo or multi gated acquisition scan (MUGA) scan showing ejection fraction (EF) > 50% and normal troponin and creatine kinase (CK) myoglobin binding (MB) (echo may be done at the time of stress test as a stress echo); within 6 months of starting treatment; however if the patient has received cardiotoxic chemotherapy such as Adriamycin, they must have had an echo or MUGA scan since completing this treatment
+Echocardiogram or multi gated acquisition (MUGA) scan with ejection fraction within normal institution limits within 28 days of registration
+Left ventricular ejection fraction >= 40% by echocardiogram (ECHO)/multi gated acquisition scan (MUGA)
+Meeting institutional criteria for allo-HCT; ejection fraction by echocardiogram or multi-gated acquisition scan (MUGA) > 40%, pulmonary function test with adjusted diffusion capacity of the lung for carbon monoxide (DLCO) >= 60%
+Left ventricular ejection fraction (LVEF) >= 50% by MUGA (multi gated acquisition) scan or echocardiogram
+Shortening fraction on echocardiogram > 28%
+Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 45%
+Cardiac ejection fraction < 50 (using motion [M]-Mode if assessment is done by echocardiogram [ECHO])
+Uncontrolled or severe cardiovascular disease or left ventricular ejection fraction < 50% as determined by echocardiogram or multigated acquisition scan (MUGA)
+Left ventricular ejection fraction (LVEF) by echocardiogram or multi gated acquisition scan (MUGA) within institutional normal limits
+Subjects should have left ventricular ejection fraction (LVEF) >= 50% by echocardiogram or multi gated acquisition (MUGA) scan performed within 4 weeks prior to treatment initiation
+Ejection fraction < 50% on echocardiogram (ECHO) or MUGA
+LVEF ? 50% by MUGA or ECHO
+A resting ejection fraction of 50% or greater which increases with exercise as demonstrated by resting/exercise multigated acquisition (MUGA) or ejection fraction of 50% or greater by echocardiogram
+A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of 50% established by multi gated acquisition scan (MUGA) or echocardiogram
+Cardiac function: Ejection fraction at rest ? 45.0% or shortening fraction of ? 27.0% by echocardiogram or radionuclide scan (MUGA).
+Patients with an ejection fraction < 45% assessed by MUGA or ---ECHO within 28 days prior to starting study cycle 1 (of midostaurin or control group)
+Left ventricular ejection fraction (LVEF) results must be >= lower limit of normal (LLN) for institution performing based on results from the multi-gated acquisition (MUGA) or echocardiogram (ECHO) done at baseline
+Left ventricular ejection fraction must be > 45% assessed by multi-gated acquisition scan (MUGA) scan or echocardiogram; no myocardial infarction within 6 months of transplant evaluation
+Left ventricular ejection fraction (LVEF) greater or equal to 50% at baseline as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA)
+Left ventricular ejection fraction (LVEF) >= 50% by multigated acquisition scan (MUGA) scan or echocardiogram (ECHO)
+Left ventricular ejection fraction (LVEF) >= 45% by multigated acquisition (MUGA) scan or echocardiogram
+Shortening fraction > 27% by echocardiogram, or
+Shortening fraction of > 25% by echocardiogram, or
+Left ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition (MUGA) scan or echocardiogram
+Left ventricular ejection fraction < 45% (evaluated by echocardiogram or MUGA scan)
+Subjects with major cardiac illness multi-gated acquisition scan (MUGA) < 50% ejection fraction (EF)
+Patients must have left ventricular ejection fraction (LVEF) > 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 4 weeks prior to registration
+Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
+Subject has left ventricular ejection fraction (LVEF) ? 50%, or below institution's lower limit of normal (whichever is lower) by echocardiogram (ECHO) or multigated acquisition (MUGA) scan.
+Have current or a history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (left ventricular ejection fraction [LVEF] < 40%, as measured by multigated acquisition [MUGA] scan or echocardiogram)
+Adequate cardiac function as defined by left ventricular ejection fraction (LVEF) >= 50% on echocardiogram or multi-gated acquisition scan (MUGA)
+Patients must have adequate cardiac function; left ventricular ejection fraction (LVEF) >= 50% as determined by multi gated acquisition (MUGA) scan or echocardiogram
+Left ventricular ejection fraction >= 50% by echocardiogram (ECHO) (preferred) or multi gated acquisition scan (MUGA)
+Has left ventricular ejection fraction (LVEF) < 45% by either echocardiogram (ECHO) or multigated acquisition scan (MUGA)
+Left ventricular ejection fraction >= institutional lower limit of normal by multi-gated acquisition (MUGA) scan or echocardiogram within 30 days of first protocol treatment
+Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 55%); appropriate correction to be used if a MUGA is performed
+Cardiac ejection fraction >50% (by echocardiogram or MUGA) within 15 days of enrollment
+Estimated cardiac ejection fraction >= 50% by echocardiogram or multi gated acquisition scan (MUGA)
+The patient’s estimated cardiac ejection fraction is < 50% by echocardiogram or MUGA
+Left ventricular ejection fraction (LVEF) >50% on echocardiography or multiple-gate acquisition (MUGA) scan.
+GROUP 2 (trametinib arm): Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
+Ejection fraction >= lower limit of normal (LLN) by echocardiogram (ECHO) (preferred) or multi gated acquisition scan (MUGA)
+Left ventricular ejection fraction (LVEF) by echocardiography (ECHO) or multiplegated acquisition (MUGA) within normal range (according to institutional standards).
+Left ventricular ejection fraction (LVEF) <50 percent (%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks before receiving the first dose of study drug.
+Left ventricular ejection fraction (LVEF) < 40% as measured by echocardiography or MUGA scan performed at Screening